Clinical efficacy of peritoneal perfusion of bevacizumab in combination with venous chemotherapy of paclitaxel and Cis-platinum on the late-stage ovarian cancer and the effect on levels of VEGF, MIF, HE4 and CA125

Abstract

Background : Often diagnosed at late stages, ovarian cancer is one of the leading causes of global cancer death. Major therapeutic choices include debugging surgery followed by chemotherapy and adjuvant therapy. Bevacizumab is an anti - VEGF medication used to treat various malignancies such as colorectal, lung, and renal cancer. The combination therapy of bevacizumab with other platinum - based medications has proved promising. Thus, researchers sought to evaluate the clinical efficacy of intraperitoneal bevacizumab combined with intravenous paclitaxel and cis platinum and their subsequent effect on blood levels of VEGF, MIF, and CA125. Materials and Methods : Ninety patients diagnosed with late - stage ovarian cancer were enrolled. Patients were divided into control and experimental groups receiving intravenous and combination chemotherapy, respectively. Clinical efficacy and alterations in tumor markers blood levels were afterward compared between the two groups. Results : Combination therapy elicited significantly higher response and total effectiveness rates with a p - value of 0.015 and 0.002, respectively. Both treatments significantly decreased tumor markers blood levels (p - value<0.05), however, combination therapy significantly induced a more profound reduction (p - value<0.01). Conclusion : Intraperitoneal bevacizumab combination therapy with intravenous paclitaxel and cis - platinum is superior to intravenous chemotherapy alone in treating late - stage ovarian cancer and increases 1 - and 2 - year survival rates.